Neonaucleoside B



Compound IDCDAMM02024
Common nameNeonaucleoside B
IUPAC name4-[2-[3-ethenyl-5-methoxycarbonyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-4-yl]ethyl]-1-[[3-ethenyl-5-methoxycarbonyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-4-yl]methyl]-9H-pyrido[3,4-b]indole-3-carboxylic acid
Molecular formulaC45H54N2O20

Experimental data

Retention time16.67
Adduct[M+Na]+
Actual mz965.323
Theoretical mz965.316
Error6.82
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.193

Identifiers and class information

Inchi keyCKFYUMFIMANAFG-NPXLHLKONA-N
SmilesO=C(O)C=1N=C(C=2NC=3C=CC=CC3C2C1CCC4C(=COC(OC5OC(CO)C(O)C(O)C5O)C4C=C)C(=O)OC)CC6C(=COC(OC7OC(CO)C(O)C(O)C7O)C6C=C)C(=O)OC
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)15
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)24
Number of reactive functional groups (#rtvFG)6
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)942.923
Computed dipole moment(dipole)7.262
Total solvent accessible surface area (SASA)1146.11
Hydrophobic component of SASA (FOSA)548.749
Hydrophilic component of SASA (FISA)409.156
Pie component of the SASA (PISA)188.208
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2453.03
Number of hydrogen bond donors (donorHB)10
Number of hydrogen bond acceptors (accptHB)30.8
Free energy of solvation of dipole (dip^2/V)0.0214964
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0849813
Globularity descriptor (glob)0.767491
Predicted polarizability in cubic angstroms (QPpolrz)78.403
Predicted hexadecane/gas partition coefficient (QPlogPC16)26.993
Predicted octanol/gas partition coefficient (QPlogPoct)59.035
Predicted water/gas partition coefficient (QPlogPw)46.23
Predicted octanol/water partition coefficient (QPlogPo/w)-1.026
Predicted aqueous solubility (QPlogS)-2.381
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.467
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.384
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.331
Predicted brain/blood partition coefficient (QPlogBB)-5.514
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.109
Predicted skin permeability, log Kp (QPlogKp)-6.093
PM3 calculated ionization potential (IP(ev))8.41
PM3 calculated electron affinity (EA(eV))0.651
Number of likely metabolic reactions (#metab)14
Prediction of binding to human serum albumin (QPlogKhsa)-1.842
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)348.061
Number of nitrogen and oxygen atoms (#NandO)22
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P11387TOP1DNA topoisomerase IT09826SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T09826DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P11387TOP1
T09826DI0095Colorectal cancer[ICD-11: 2B91]P11387TOP1
T09826DI0238Lung cancer[ICD-11: 2C25]P11387TOP1
T09826DI0321Ovarian cancer[ICD-11: 2C73]P11387TOP1
T09826DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P11387TOP1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3

Copyright © 2025